US market focus Sun Pharma US drives the majority of revenue with the United States as its single largest market, presenting strong cross-sell and product expansion opportunities for US-focused distributors, pharmacies, and specialty retailers.

Generics and API A large basket of US generics and a growing API business provide multiple touchpoints for partnerships with contract manufacturers, healthcare distributors, and pharmacovigilance services to accelerate approvals and supply continuity.

Strategic expansions Recent investments in Canada and China indicate readiness to broaden geographic reach; sales teams can target regional importers, distributors, and hospital networks seeking diversified supply sources.

Recall risk signals Voluntary recall of carbamazepine highlights quality and regulatory vigilance; opportunity to position as a trusted supplier with robust quality assurance, expedited regulatory support, and risk mitigation services for buyers.

Leadership and momentum Leadership recognition and ongoing funding for acquisitions suggest confidence and growth trajectory; align with strategic accounts and M&A-friendly partners looking to capitalize on Sun Pharma’s scale and pipeline.